ANIPHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering ANI Pharmaceuticals, Inc. hold a median 12-month price target of $110 — +45.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ANI Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (50): Analysts have, on balance, been cutting their forecasts.
Size (39): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANIP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +45.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | $91 → $90 |
| 10 Aug 2026 | Guggenheim | Maintains | Buy | $124 → $119 |
| 17 July 2026 | Canaccord Genuity | Initiates | Hold | $91 |
| 17 July 2026 | Canaccord Genuity | Initiates | Hold | — |
| 10 July 2026 | Guggenheim | Reiterates | Buy | — |
| 10 July 2026 | Guggenheim | Reiterates | Buy | $124 |
| 16 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 9 Oct 2025 | Truist Securities | Maintains | Hold | — |
| 24 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 11 Aug 2025 | Truist Securities | Maintains | Hold | — |
| 8 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 July 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 12 May 2025 | Guggenheim | Reiterates | Buy | — |
| 21 Apr 2025 | Truist Securities | Maintains | Hold | — |
| 11 Apr 2025 | Guggenheim | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIP appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 56% of US stocks
Cheaper than 37% of US stocks
Cheaper than 42% of US stocks
Higher than 76% of US stocks
Higher than 90% of US stocks
Higher than 76% of US stocks
Higher than 72% of US stocks
Higher than 72% of US stocks
Higher than 81% of US stocks
Higher than 78% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ANI Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ANI Pharmaceuticals lowered its guidance for Cortrophin, putting increased pressure on the company to deliver stronger growth in the second half of the year.
Why it matters — A Cortrophin guidance cut raises the stakes for ANIP's execution going forward, making second-half performance critical for meeting revised expectations.
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook now face a key test as Cortrophin execution risk rises, according to a Zacks Investment Research item. The article frames the company's prospects as being weighed against increasing execution risk for the Cortrophin product.
Why it matters — A ANIP watcher would care because Cortrophin execution risk is emerging as a central factor that could affect the company's near-term performance amid an otherwise attractive valuation and 2026 growth outlook.
ANI Pharmaceuticals beat second-quarter earnings and sales estimates, but shares fell after the company lowered its 2026 revenue outlook for Cortrophin Gel.
Why it matters — ANIP watchers would care because the reduced Cortrophin Gel revenue outlook signals weaker expectations for a key product line despite the earnings beat.
ANI Pharmaceuticals reported upbeat earnings for the second quarter on Friday. Following the results, analysts slashed their forecasts on the company.
Why it matters — Analysts revising down their forecasts after quarterly results points to a shift in expectations for ANIP's financial outlook.
ANI Pharmaceuticals, Inc. held its Q2 2026 earnings call, the transcript of which was published on Seeking Alpha.
Why it matters — Earnings call transcripts provide ANIP watchers with direct insight into management's discussion of quarterly financial results and operational performance.
The 8 Wall Street analysts covering ANI Pharmaceuticals, Inc. have a median 12-month price target of $110, with estimates ranging from $90 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering ANI Pharmaceuticals, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ANI Pharmaceuticals, Inc. 95 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, ANI Pharmaceuticals, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +45.3% from the last close, and Ticker Nerd's factor model ranks ANI Pharmaceuticals, Inc. 95 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ANI Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $121 over the next 12 months.
ANI Pharmaceuticals, Inc. returned -17.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth". ANI Pharmaceuticals lowered its guidance for Cortrophin, putting increased pressure on the company to deliver stronger growth in the second half of the year.
ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. It specializes in a range of dosage forms, including liquid, powder, oral solid-dose products, injectables, softgel capsules, semi-solids, topicals, and controlled substances. The company operates through key segments: Rare Disease, featuring novel therapeutics in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, such as Purified Cortrophin Gel, ILUVIEN, and YUTIQ; Generics, leveraging R&D expertise and U.S.-based manufacturing for products like Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, and Vancomycin; and Established Brands. ANI Pharmaceuticals Inc. focuses on areas like narcotics, oncolytics, hormones, steroids, and complex formulations including extended-release and combination products. Primarily serving the United States and Canada, it emphasizes high-quality therapeutics through operational excellence and North American manufacturing capabilities. Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals Inc. plays a vital role in addressing patient needs across specialized pharmaceutical markets.
CEO Mr. Nikhil Lalwani · 970 employees · United States · https://www.anipharmaceuticals.com